Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Protagonist Therapeutics Inc (NASDAQ: PTGX) closed the day trading at $85.79 down -3.97% from the previous closing price of $89.34. In other words, the price has decreased by -$3.97 from its previous closing price. On the day, 2.23 million shares were traded. PTGX stock price reached its highest trading level at $90.015 during the session, while it also had its lowest trading level at $84.11.
Ratios:
For a better understanding of PTGX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.67. For the most recent quarter (mrq), Quick Ratio is recorded 13.05 and its Current Ratio is at 13.05. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $72.
On September 12, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $73.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $72.Citigroup initiated its Buy rating on June 17, 2025, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when MOLINA ARTURO MD sold 2,712 shares for $84.77 per share. The transaction valued at 229,896 led to the insider holds 81,180 shares of the business.
Waddill William D. sold 12,000 shares of PTGX for $979,480 on Oct 10 ’25. The Director now owns 5,130 shares after completing the transaction at $81.62 per share. On Oct 10 ’25, another insider, WILLIAM WADDILL, who serves as the Director of the company, bought 12,000 shares for $67.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 5363218944 and an Enterprise Value of 4797851136. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 135.44, and their Forward P/E ratio for the next fiscal year is 100.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.70 while its Price-to-Book (P/B) ratio in mrq is 8.30. Its current Enterprise Value per Revenue stands at 22.932 whereas that against EBITDA is 239.533.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.25, which has changed by 1.15329 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $96.54, while it has fallen to a 52-week low of $33.70. The 50-Day Moving Average of the stock is 3.43%, while the 200-Day Moving Average is calculated to be 42.07%.
Shares Statistics:
Over the past 3-months, PTGX traded about 1.19M shares per day on average, while over the past 10 days, PTGX traded about 1116430 shares per day. A total of 62.45M shares are outstanding, with a floating share count of 59.09M. Insiders hold about 5.47% of the company’s shares, while institutions hold 110.21% stake in the company. Shares short for PTGX as of 1764288000 were 5883017 with a Short Ratio of 4.94, compared to 1761868800 on 5465729. Therefore, it implies a Short% of Shares Outstanding of 5883017 and a Short% of Float of 11.270001.
Earnings Estimates
Currently, 9.0 analysts are dedicated to thoroughly evaluating and rating the performance of Protagonist Therapeutics Inc (PTGX) in the stock market.The consensus estimate for the next quarter is -$0.43, with high estimates of $0.06 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.26 and -$2.33 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is $1.06, with 9.0 analysts recommending between $5.04 and -$2.36.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $258.9M, while the lowest revenue estimate was $38.58M, resulting in an average revenue estimate of $66.81M. In the same quarter a year ago, actual revenue was $434.43MBased on 10 analysts’ estimates, the company’s revenue will be $273.47M in the next fiscal year. The high estimate is $525M and the low estimate is $20M.
